Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 1976;292(2):113-8.
doi: 10.1007/BF00498580.

Responsiveness of isolated canine cerebral and peripheral arteries to ergotamine

E Müller-Schweinitzer
Comparative Study

Responsiveness of isolated canine cerebral and peripheral arteries to ergotamine

E Müller-Schweinitzer. Naunyn Schmiedebergs Arch Pharmacol. 1976.

Abstract

Changes in tension of spiral strips from dog saphenous, external carotid and basilar arteries were monitored isometrically. Serotonin (5-HT) contracted the 3 arterial preparations in about the same concentration range. Compared with noradrenaline (NA) (100%) the efficacy of 5-HT was about 60% on saphenous, 150% on external carotid and about 500% on basilar arteries. Ergotamine (E) stimulated the 3 vascular preparations in concentrations about 100 times lower than 5-HT. Compared with NA the efficacy of E was about 20% on saphenous, 50% on external carotid and 200% on basilar arteries. Compared with 5-HT (100%) however, E had similar constrictor activities in the 3 arteries. It seemed likely therefore that 5-HT receptors are involved in the vasoconstrictor activity of E. Evidence for this was obtained in experiments in which cyproheptadine (Cy), a 5-HT antagonist, was used. For antagonism of E concentrations of Cy about 6 times higher than those required to inhibit 5-HT were necessary, whereas for antagonism of NA about 500 times higher Cy concentrations were necessary. The results suggest that on canine arterial vascular smooth muscle the constrictor activity of E is mediated mainly through serotoninergic receptor sites.

PubMed Disclaimer

References

    1. J Pharm Pharmacol. 1972 Aug;24(8):668 - PubMed
    1. Drugs. 1972;3(3):153-8 - PubMed
    1. Brain. 1965 Dec;88(5):997-1010 - PubMed
    1. Neurology. 1963 Sep;13:772-8 - PubMed
    1. Br J Pharmacol Chemother. 1957 Jun;12(2):232-9 - PubMed

Publication types